European and Developing Countries Clinical Trials Partnership

Details of this partnership including related links and fact sheets

Poverty-related infectious diseases have huge negative impacts on health, society and the economy. They particularly affect the world’s poorest and most marginalised communities. More than 1 billion people, including 400 million children, are suffering from the three major poverty-related diseases — HIV/AIDS, malaria and tuberculosis — and the neglected infectious diseases combined. Malaria and tuberculosis alone lead to the death of an estimated 2.1 million people annually. The poverty-related diseases increase infirmity and insecurity, undermine productivity, and thus perpetuate the cycle of poverty. Sub-Saharan Africa is disproportionately affected; approximately 90 % of all malaria-related deaths occur in this region which also accounts for 68 % of all people living with HIV and 72 % of AIDS-related deaths.

The European & Developing Countries Clinical Trials Partnership (EDCTP) was created as a European response to the global health crisis related to poverty-related infectious diseases. This research funding partnership aims to accelerate the clinical development of new or improved medicinal products while also strengthening African clinical research capacity. EDCTP is a partnership between countries in Europe and sub-Saharan Africa, and the European Union.

EDCTP programmes

The first EDCTP programme (EDCTP1, 2003-2015) was launched in 2003 by 16 European countries and the European Union to support clinical trials and research capacity development to fight HIV/AIDS, malaria and tuberculosis in Africa. EDCTP1 supported 254 projects with EUR 378 million, involving 194 African and 72 European research institutions. African researchers led more than 70% of the projects.

The EU's commitment to EDCTP resulted in an increased H2020 budget for the second programme (EDCTP2, 2014-2024), of up to EUR 683 million. This enabled an expanded scope and targeted investments in the neglected infectious diseases, diarrhoeal diseases, lower respiratory tract infections, and (re˗)emerging infectious diseases with pandemic potential. The EDCTP Association implements EDCTP2 and currently has 30 member countries: 14 European and 16 African countries. Between 2014-2017, EDCTP2 has already awarded EUR 255 million in grant funding: 50 projects including at least one clinical trial, 58 fellowships for researchers from sub-Saharan Africa, and 13 grants to strengthening the regulatory and ethics review capacities in Africa. The grants involve altogether 206 sub-Saharan institutions and 95 European institutions.

EDCTP2 contributes to the European Union as strong global player in health research and complements other EU initiatives with third countries, such as GLoPID-R. The Global Research Collaboration for Infectious Diseases is a network of funders, chaired by the EU that facilitates an effective research response within 48 hours of a significant outbreak of a new or re-emerging infectious disease with pandemic potential. EDCTP2 also supports EU initiatives on open access to clinical trials results and open clinical data, research ethics and anti-microbial resistance.